Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Current Deferred Revenue (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Current Deferred Revenue for 6 consecutive years, with $2.6 million as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue fell 77.61% to $2.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.6 million through Dec 2025, down 77.61% year-over-year, with the annual reading at $2.6 million for FY2025, 77.61% down from the prior year.
  • Current Deferred Revenue for Q4 2025 was $2.6 million at TScan Therapeutics, down from $5.2 million in the prior quarter.
  • The five-year high for Current Deferred Revenue was $19.2 million in Q2 2023, with the low at $2.6 million in Q4 2025.
  • Average Current Deferred Revenue over 5 years is $9.8 million, with a median of $10.4 million recorded in 2024.
  • The sharpest move saw Current Deferred Revenue surged 161.67% in 2023, then crashed 77.61% in 2025.
  • Over 5 years, Current Deferred Revenue stood at $11.4 million in 2021, then tumbled by 66.05% to $3.9 million in 2022, then surged by 161.67% to $10.1 million in 2023, then increased by 15.4% to $11.7 million in 2024, then plummeted by 77.61% to $2.6 million in 2025.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $2.6 million, $5.2 million, and $7.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.